<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771689</url>
  </required_header>
  <id_info>
    <org_study_id>2021P000553</org_study_id>
    <nct_id>NCT04771689</nct_id>
  </id_info>
  <brief_title>Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients</brief_title>
  <official_title>Assess the Efficacy of Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical study evaluating the effect of buprenorphine/naloxone (bup/nx)&#xD;
      sublingual film on postoperative pain management in opioid-tolerant patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Pain Scores</measure>
    <time_frame>through study completion, an average of 6 days</time_frame>
    <description>To examine changes in pain scores daily from the day of surgery to the hospital discharge day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative Opioid Consumption</measure>
    <time_frame>through study completion, an average of 6 days</time_frame>
    <description>To compare opioid consumption after surgery between the buprenorphine/naloxone group and the standard medication regiment group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Hospital Stay</measure>
    <time_frame>through study completion, an average of 6 days</time_frame>
    <description>To compare the length of hospital stay after surgery between the buprenorphine/naloxone group and the standard medication regiment group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-operative Pain</condition>
  <arm_group>
    <arm_group_label>Buprenorphine/Naloxone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will take a maximum dose of 4 mg buprenorphine and 1 mg naloxone with concurrent administration of other intravenous or oral opioids needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Medication Regiment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects will take conventional intravenous or oral opioid management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine/Naloxone</intervention_name>
    <description>Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for the length of their hospital stay, at least 6 days.</description>
    <arm_group_label>Buprenorphine/Naloxone</arm_group_label>
    <other_name>Suboxone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Opioid tolerance, defined as the daily use of greater than or equal to 60mg of oral&#xD;
             morphine or an equianalgesic dose of any other opioid for more than 7 days immediately&#xD;
             prior to the surgery&#xD;
&#xD;
          2. Undergoing orthopedic or general surgery&#xD;
&#xD;
          3. 18 years of age or older&#xD;
&#xD;
          4. Willing and able to adhere to the study protocol and follow-up schedule&#xD;
&#xD;
          5. Able to provide written informed consent to participate in the clinical trial&#xD;
&#xD;
          6. If female and of childbearing potential, agree to use an effective method of birth&#xD;
             control approved by the study investigators throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Buprenorphine or buprenorphine/naloxone use in the last two weeks&#xD;
&#xD;
          2. Patients receiving pre-, intra-, or post-operative regional blocks or neuraxial&#xD;
             anesthesia&#xD;
&#xD;
          3. Patients receiving postoperative ketamine or lidocaine boluses or infusions&#xD;
&#xD;
          4. Patients receiving postoperative nonsteroidal anti-inflammatory drugs (NSAIDs) for&#xD;
             pain control&#xD;
&#xD;
          5. Diagnosis of severe medical or psychiatric conditions contraindicated for bup/nx&#xD;
             treatment&#xD;
&#xD;
          6. Liver disease, including clinically significant transaminitis, active hepatitis&#xD;
             infection, cirrhosis with evidence of impaired synthetic function&#xD;
&#xD;
          7. Anticipated deterioration of health due to discontinuation of medications that are&#xD;
             contraindicated with bup/nx&#xD;
&#xD;
          8. Positive pregnancy test for women of childbearing potential&#xD;
&#xD;
          9. Known allergy or sensitivity to bup/nx&#xD;
&#xD;
         10. Anticipation that the subject may need to initiate pharmacological treatment during&#xD;
             the trial that is deemed unsafe by the study physician or could prevent study&#xD;
             completion&#xD;
&#xD;
         11. Current participation in additional pharmacologic research study&#xD;
&#xD;
         12. Active suicidal ideation as determined by PI or study clinician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karina de Sousa, BS</last_name>
    <phone>617-724-6102</phone>
    <email>kdesousa1@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Grace Mogren, BS</last_name>
    <phone>617-724-6102</phone>
    <email>gmogren@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karina de Sousa</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Karina de Sousa, BS</last_name>
      <phone>617-724-6102</phone>
      <email>kdesousa1@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grace Mogren, BS</last_name>
      <phone>617-724-6102</phone>
      <email>gmogren@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Yi Zhang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/translationalpainresearch/</url>
    <description>Massachusetts General Hospital Center for Translational Pain Research</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Yi Zhang, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <keyword>pain management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified data may be shared with other researchers in the future.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

